Ani Pharmaceuticals (ANIP) Research & Development (2010 - 2026)

Ani Pharmaceuticals has disclosed Research & Development across 17 years of filings, most recently posting $14.7 million for Q2 2026.

• In Q2 2026, Research & Development fell 10.81% year-over-year to $14.7 million; the TTM figure through Jun 2026 stood at $49.9 million (down 7.35% YoY), while the FY2025 annual figure was $51.7 million, up 15.89% from the prior year.
• Research & Development came in at $14.7 million for Q2 2026 at Ani Pharmaceuticals, up from $10.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $16.6 million in Q4 2024 to a low of $4.2 million in Q2 2022.
• Average Research & Development over 5 years is $9.9 million, with a median of $10.3 million recorded in 2024.
• Year-over-year, Research & Development jumped 211.77% in 2022 and decreased 26.34% in 2025.
• Over 5 years, Research & Development stood at $5.2 million in 2022, then surged by 88.95% to $9.9 million in 2023, then jumped by 68.7% to $16.6 million in 2024, then retreated by 26.34% to $12.3 million in 2025, then rose by 20.28% to $14.7 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $14.7 million in Q2 2026, $10.6 million in Q1 2026, and $12.3 million in Q4 2025.